Tested treatment for kidney injury from multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial studies HFR-SUPRA, a kidney-focused treatment, for people with multiple myeloma who develop sudden kidney failure that requires dialysis. It aims to improve kidney outcomes after this serious complication.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- Your multiple myeloma is new (starting recently).
- You have sudden kidney injury and your kidney filtering is very low (eGFR under 15) and you need hemodialysis.
- The kidney problem is thought to be “cast nephropathy” after other common causes are ruled out (such as blockage, high calcium, amyloidosis, light-chain deposits, contrast dye injury, or medication-related kidney injury).
- Your blood light chain level is above 500 mg/L.
- You do not have long-term kidney disease for at least 3 months (eGFR under 60 for 3+ months).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether finerenone (a medicine that helps protect the kidneys) can improve recovery from acute kidney injury (sudden kidney failure) in hospitalized patients. Participation involves taking the study drug or a placebo while in the hospital.
This trial tests a new drug called SHR-3836 for patients with multiple myeloma that has come back or stopped responding to treatment. The goal is to see if the drug is safe and how it works against the cancer.
This trial tests a special device that filters parts of the blood to calm inflammation in people with severe acute kidney injury in the ICU. It may help improve recovery and reduce complications by “deactivating” certain immune cells.
This study looks at two different blood thinners—regional citrate and systemic heparin—used during continuous kidney replacement therapy (CKRT) for acute kidney injury (AKI). It aims to learn which works better and safer.
This study tests a special filter (HA380 column) used during dialysis or ECMO to remove harmful substances from the blood. It is for critically ill patients with severe infection, injury, or breathing problems who also need kidney or lung support.
This trial tests whether adding a special filter called pHA130 to your regular dialysis treatments can better remove certain waste products from your blood and improve your quality of life. It's for people who have been on dialysis for at least 3 months and meet a few health requirements.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.